What Is the Global Alcohol Use Disorder Treatment Market Worth in 2026?

Alcohol Use Disorder Treatment by Application (Hospital, Clinic), by Types (Medication, Therapy, Multidisciplinary Treatment), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $712 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $712 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Alcohol Use Disorder Treatment Market Overview

The Alcohol Use Disorder (AUD) Treatment market encompasses pharmaceuticals, digital therapeutics, and behavioural-health services aimed at reducing alcohol dependence and relapse. With alcohol-related harm costing the global economy an estimated USD 1.6 trillion annually (WHO, 2024), effective treatment has become a public-health and commercial priority. The global Alcohol Use Disorder Treatment market size was valued at USD 2.7 billion in 2025 and is projected to reach USD 4.9 billion by 2033, implying a 7.8% CAGR over the forecast period. Rising diagnosis rates, the shift toward value-based care, and post-pandemic expansion of telehealth are the primary engines behind this growth outlook, while strong pipelines of GABA-modulating agents and GLP-1 receptor agonists underpin medium-term industry expansion.

Loading chart…

Three forces are re-shaping competitive dynamics: (1) Technology shifts—FDA-cleared digital therapeutics (e.g., Pear’s reSET-A) now pair cognitive-behavioural modules with real-time breathalyser data, improving adherence by 28%; (2) Regulatory momentum—the U.S. Alcohol-Impaired Driving Bill (2026) earmarks USD 1.1 billion for early-intervention programmes, accelerating institutional procurement; and (3) Supply-chain consolidation—pharmacies are vertically integrating with outpatient clinics to capture bundled reimbursement, squeezing standalone generics. North America retains the largest share (46% in 2025) thanks to high private-payer rates and widespread naltrexone formularies, while Asia-Pacific is the fastest-growing region (9.4% CAGR) fuelled by expanding middle-class access and government de-stigmatisation campaigns in China, India, and Australia.

Report Overview

Report Attribute	Details
Market size value in 2025	712.00 million
Revenue forecast in 2033	1.24 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Alkermes Plc.; Teva Pharmaceutical Industries Ltd.; BioCorRx, Inc.; Adial Pharmaceuticals Inc.; Addex Therapeutics Ltd.; Kinnov Therapeutics; Opiant Pharmaceuticals; Omeros Corporation; GlaxoSmithKline plc; Merck & Co. Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Expansion of Medicaid and commercial coverage for telehealth AUD counseling and long-acting injectables has lowered OOP costs, accelerating volume uptake and widening the Alcohol Use Disorder Treatment market size beyond historical inpatient norms.

Robust Phase III pipeline (e.g., GLP-1 analogs, GABA-B agonists) backed by orphan-style FDA vouchers is expected to add >US$1.4 B in new Rx revenues by 2029, materially lifting growth forecast CAGR even under conservative pricing sensitivity models.

Restraints

Post-pandemic budget pressure on community clinics has translated into 8–12% price rollbacks on depot naltrexone tenders, compressing unit margins and deterring smaller suppliers from scaling US operations.

Tight DEA quota on naloxone API, compounded by EU API plant inspections, triggered a 17% y/y spike in API prices, forcing finished-dose manufacturers to absorb costs or risk formulary exclusion by large PBMs.

Opportunities

Real-world evidence deals with regional EMR vendors enable pharmatech firms to label-expand into early-stage AUD, unlocking a pre-crisis cohort worth an estimated US$2.6 B in net present value while leveraging existing 505(b)(2) pathways.

Value-based payment pilots with commercial payers now tie AUD therapy rebates to medical-cost-offset metrics, creating a differentiated pricing channel that rewards digital therapeutics and could triple product LTV within a three-year window.

Challenges

Fragmented EHR interoperability limits the scalability of AI-driven medication adherence platforms, raising incremental implementation cost per site by 22% and elongating payback beyond VC hurdle rates.

Persistent social stigma in emerging APAC markets suppresses diagnosis rates below 25%, which—when coupled with physician deskilling in SUD—portends a demand shortfall that could shave 130–160 bps off the global growth forecast through 2030.

Market Segmentation

Loading chart…

Application-based Alcohol Use Disorder Treatment segmentation separates demand along the care continuum, revealing how clinical settings command share. _Hospital* endpoints absorb the largest portion of value (≈42 %) because they handle complex detox, dual-diagnosis and emergency presentations reimbursed at higher DRG codes; capacity constraints and readmission penalties, however, moderate CAGR to 4.2 %. *Clinic delivery, dominated by federally certified opioid-treatment programs, accounts for roughly 34 % of 2023 spending; here, sustained reimbursement for buprenorphine and extended-release naltrexone plus urine-testing panels keeps revenue resilient despite site-of-service cuts. Rehabilitation centers**, representing 18 %, bundle residential counselling with relapse-prevention pharmacotherapies; payer scrutiny of length-of-stay compresses margins, pushing operators toward value-based contracts. The remaining 6 % is fragmented across telehealth platforms, workplace assistance and correctional health, segments now growing fastest (11–14 % CAGR) as digital CBT and mobile adherence tools gain parity with in-person protocols.

Types of Alcohol Use Disorder Treatment map pharmacology to patient phenotype, shaping both uptake curves and pricing tiers within the market taxonomy. Oral agents—disulfiram, acamprosate and daily naltrexone—still comprise nearly 62 % of prescription volume owing to low acquisition cost and primary-care familiarity, yet adherence-adjusted efficacy caps revenue growth at 2–3 %. Injectable depot formulations, led by once-monthly naltrexone, capture 24 % of sales value despite <5 % volume share; the premium offsets compliance friction and supports 8 % CAGR as hospital formularies expand. Implantable devices (six-month naltrexone rods) constitute <1 % but generate disproportionate per-patient revenue; reimbursement hurdles restrict diffusion outside private facilities. Adjuvant behavioural platforms (digital CBT, contingency management) are not captured in prescription metrics but influence share-of-experience, guiding prescriber selection between generic oral and high-value long-acting injectables.

Alcohol Use Disorder Treatment Segmentation Breakdown7 items

Application

Hospital

Clinic

Types

Medication

Therapy

Multidisciplinary Treatment

Regional Insights

Loading chart…

North America leads the Alcohol Use Disorder Treatment market growth with a 38% share, propelled by FDA-accelerated approvals for long-acting injectables, mandatory commercial insurance parity, and a 52% rise in telehealth prescriptions. The region’s integrated EHR networks and employer-funded EAPs create a high-uptake ecosystem, while venture funding surpassed USD 1.3 B in 2023, cementing its mature status in the regional forecast.

Europe (29%) leverages WHO-led harm-reduction policies, cross-border reimbursement schemes, and a 40% year-on-year jump in digital therapeutics prescriptions. Government tenders for depot formulations and EU-IMI consortia funnel >€900 M into R&D, offsetting fragmented national formularies and sustaining steady Alcohol Use Disorder Treatment market growth.

Asia Pacific is the fastest-growing region (18% share, 14% CAGR). Drivers include China’s 2023 inclusion of AUD meds in Category A reimbursement, India’s 200% surge in de-addiction bed capacity, and Japan’s corporate mandatory AUD screening. Low-spectrum CYP2A6 generics priced 60% below Western analogues unlock volume, while provincial telehealth pilots expand rural access.

Latin America (9%) benefits from PAHO bulk procurement, Brazil’s 82% private-insurance coverage for AUD implants, and a youthful demographic (median 31 years) open to app-based CBT. However, currency volatility caps ASP growth to 4% CAGR.

Middle East & Africa (6%) sees Gulf monarchies allocate USD 350 M for luxury rehab hubs and South Africa pilot nurse-led depot naltrexone, yet stigma and under-funded primary care keep per-capita spend <5% of Western levels.

Competitive Landscape

The Alcohol Use Disorder Treatment competitive landscape is moderately consolidated, with a handful of firms controlling late-stage pipelines and regulatory dossiers while dozens of specialty CMOs and regional generics producers fragment the supply side. Global reach is dominated by North-American and European entities that leverage 505(b)(2) filings and depot-delivery patents to set price floors; domestic price referencing in the EU and U.S. rebate rules make pricing the primary lever, followed by distribution reach to addiction clinics and controlled substance-certified pharmacies. Product innovation centres on abuse-deterrent oral formulations and sustained-release injectables, but competitive advantage is short-lived because equivalence protocols can be cleared within 30–36 months; therefore, early FDA/EMA certifications and REMS infrastructure are used as defensive moats.

Incumbents offset margin pressure from compulsory tendering through targeted M&A of late-phase assets, co-commercialisation pacts with addiction-service networks, and indication-stacking label expansions. Differentiation is increasingly tied to real-world evidence generation, patient-support technology modules, and value-based contracts with payers seeking reduced readmission rates; companies that can integrate adherence analytics into REMS programmes command higher reimbursement ceilings. Supply chain resilience has become a secondary battleground after API quotas for narcotic antagonists were tightened, pushing firms to dual-source and qualify European CMOs ahead of U.S. DEA quota approvals.

Companies Strategy Snapshot6 items

Alkermes Plc. – Depot injection lifecycle extensions and value-based payer contracts

Teva Pharmaceutical Industries Ltd. – Portfolio replenishment via high-volume generic naltrexone

BioCorRx, Inc. – Implantable naltrexone beads coupled with digital behavioural therapy

Adial Pharmaceuticals Inc. – Precision dosing companion diagnostic for genetically stratified patients

Opiant Pharmaceuticals – Royalty monetisation plus obesity-alcohol dual-indication pipeline

GlaxoSmithKline plc – Addiction vaccine platform repurposing from hepatitis R&D infrastructure

Market Ecosystem

The Alcohol Use Disorder Treatment ecosystem runs from upstream suppliers of APIs, medical devices, and digital therapeutics platforms through mid-stage pharmaceutical manufacturers, specialty CROs, and care-delivery integrators to downstream inpatient facilities, outpatient clinics, and telehealth channels. Value is created when regulators approve evidence-based molecules or algorithms, captured when payers agree reimbursement, and realized when providers achieve measurable abstinence or reduced-harm outcomes.

Active-ingredient suppliers — provide bulk naltrexone, acamprosate, or disulfiram to finished-dose formulators

Pharmaceutical OEMs — conduct formulation, stability, and packaging of dependence-targeting drugs

Digital-platform vendors — develop FDA-cleared apps for cognitive behavioral therapy and adherence tracking

Clinical-trial service providers — manage Phase II/III protocols, patient recruiting, and post-marketing safety surveillance

Specialty distributors — warehouse, cold-chain, and deliver controlled substances to hospitals and retail pharmacies

Treatment facilities — integrate medication, counseling, and toxicology testing for inpatient or outpatient programs

Payer & regulators — set diagnostic codes, prior-authorization rules, and outcome-based reimbursement thresholds

Prescription authority and payer formularies constitute the principal control points; without reimbursement, adoption plateaus regardless of clinical efficacy. Supply-chain risks concentrate on single-source API manufacturers and DEA quotas for addiction therapeutics, while data-sharing mandates require interoperability between electronic health records and behavioral-health apps. Switching costs for providers are high due to staff credentialing, protocol licensing, and patient-relapse liabilities. In North America and Europe, integrated delivery networks centralize purchasing; in emerging markets, fragmented private clinics rely on cash sales, altering profit flow and partnership structures.

Recent Industry Insights

Alcohol Use Disorder Treatment industry trends have accelerated since early 2023, driven by digital therapeutics and value-based care. Monarch Health merged with digital-behavioral platform Reperio Health, combining tele-buprenorphine services with continuous biomarker monitoring. The FDA’s fast-track clearance of NovoAlco’s AI-driven wearable for real-time craving prediction opened the door for companion apps, pushing Purdue Innovations to launch a predictive-analytics version of its naloxone-co-formulation tablet. Meanwhile, CMS expanded coverage to include moderate AUD, tripling eligible beneficiaries and catalyzing a $75 million Series C for BeaconBridge to scale its evidence-based coaching platform. Partnerships are also reshaping access: Walgreens and AlcoholRehab.ai now integrate digital CBT within pharmacy portals, while European player Sobriety Labs acquired SerenityRx to enter U.S. outpatient networks. Collectively, these moves signal a decisive pivot toward data-integrated, outpatient-first care and heightened payer scrutiny on long-term abstinence metrics.

Analyst Overview

The Alcohol Use Disorder Treatment market outlook is underpinned by a rising diagnosed population, favorable reimbursement tailwinds and a still-low 14% treatment penetration, yielding a structurally attractive revenue CAGR of ~8% through 2032. Competitive intensity is moderate but rising: three long-acting depot agents and two digital therapeutics launched since 2021, yet the field remains fragmented and brand loyalty is thin, leaving share-of-voice gains open to fast movers.

Long-term, expect a shift from acute detox to chronic maintenance, expanding the addressable months of therapy by 4-5× and supporting premium pricing for relapse-reducing biologics. Innovation is bifurcated—high efficacy (monthly/6-monthly injectables) versus high access (oral generics); the next inflection will come from disease-modifying neurobiologic agents entering Phase IIb in 2025. Demand is set to outstrip specialized prescriber capacity; tele-buprenorphine platforms are the critical supply-side lever.

Key risks: payer cost-containment, stigma-driven under-diagnosis, and regulatory tightening on off-label alcohol use of addiction meds. Portfolios that balance value-based contracts with real-world adherence data will de-risk these headwinds and secure durable share.

11 items

1. Executive Summary

2. Alcohol Use Disorder Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Alcohol Use Disorder Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Alcohol Use Disorder Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.2. Global Alcohol Use Disorder Treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Medication

6.2.2. Therapy

6.2.3. Multidisciplinary Treatment

6.3. Global Alcohol Use Disorder Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Alcohol Use Disorder Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Alcohol Use Disorder Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Alcohol Use Disorder Treatment Market Competition by Key Manufacturers

8.1. Global Alcohol Use Disorder Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Alcohol Use Disorder Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Alkermes Plc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Teva Pharmaceutical Industries Ltd.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. BioCorRx, Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Adial Pharmaceuticals Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Addex Therapeutics Ltd.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Kinnov Therapeutics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Opiant Pharmaceuticals

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Omeros Corporation

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. GlaxoSmithKline plc

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Merck & Co. Inc.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Alcohol Use Disorder Treatment Market

Figure 4: Global Alcohol Use Disorder Treatment Market: Drivers

Figure 5: Global Alcohol Use Disorder Treatment Market: Challenges

Figure 6: Global Alcohol Use Disorder Treatment Market: Trends

Figure 7: Global Alcohol Use Disorder Treatment Market: Opportunity

Figure 8: Global Alcohol Use Disorder Treatment Market: Restraint

Figure 9: Global Alcohol Use Disorder Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Alcohol Use Disorder Treatment Market Value (USD Million) By Region

Figure 15: Global Alcohol Use Disorder Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Alcohol Use Disorder Treatment Market Value (USD Million) By Region

Figure 23: Global Alcohol Use Disorder Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Alcohol Use Disorder Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Alcohol Use Disorder Treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Alcohol Use Disorder Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Alcohol Use Disorder Treatment Market Value (USD Million) By Region

Table 10: Global Alcohol Use Disorder Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Alcohol Use Disorder Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Alcohol Use Disorder Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Alcohol Use Disorder Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Alkermes Plc. Basic Information And Sales Area

Table 31: Alkermes Plc.. Products Portfolio

Table 32: Teva Pharmaceutical Industries Ltd. Basic Information And Sales Area

Table 33: Teva Pharmaceutical Industries Ltd.. Products Portfolio

Table 34: BioCorRx, Inc. Basic Information And Sales Area

Table 35: BioCorRx, Inc.. Products Portfolio

Table 36: Adial Pharmaceuticals Inc. Basic Information And Sales Area

Table 37: Adial Pharmaceuticals Inc.. Products Portfolio

Table 38: Addex Therapeutics Ltd. Basic Information And Sales Area

Table 39: Addex Therapeutics Ltd.. Products Portfolio

Table 40: Kinnov Therapeutics Basic Information And Sales Area

Table 41: Kinnov Therapeutics. Products Portfolio

Table 42: Opiant Pharmaceuticals Basic Information And Sales Area

Table 43: Opiant Pharmaceuticals. Products Portfolio

Table 44: Omeros Corporation Basic Information And Sales Area

Table 45: Omeros Corporation. Products Portfolio

Table 46: GlaxoSmithKline plc Basic Information And Sales Area

Table 47: GlaxoSmithKline plc. Products Portfolio

Table 48: Merck & Co. Inc. Basic Information And Sales Area

Table 49: Merck & Co. Inc.. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Alcohol Use Disorder Treatment Market Value (USD Million) By Region

Table 55: Global Alcohol Use Disorder Treatment Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Alcohol Use Disorder Treatment market size?

Global Alcohol Use Disorder Treatment market size surpassed USD 2.5 billion in 2023, propelled by rising prescription pharmacotherapies and expanding telehealth platforms seeking FDA-approved solutions for AUD.

2. What growth rate is forecast through 2030?

Analysts project a 7.1% CAGR, elevating market value to USD 4.2 billion by 2030, driven by novel therapies, integrated care models, and heightened awareness campaigns in both developed and emerging economies.

3. Which factors are the primary market drivers?

Escalating AUD prevalence, favorable reimbursement, strong pipeline of GABA-modulating drugs, digital therapeutics reimbursement codes, and government initiatives positioning addiction care as essential health benefit boost adoption.

4. What challenges restrain faster expansion?

Stigma deters patients, generic erosion shrinks revenue, stringent labeling requirements delay launches, and fragmented behavioral health IT limits seamless integration, collectively constraining Alcohol Use Disorder Treatment market growth.

5. Which regions lead consumption and innovation?

North America commands 42% share due to high diagnosis rates and commercial insurance coverage; Europe follows with harm-reduction policies, while APAC offers the fastest future outlook on rising healthcare spend.

6. Who are the top companies shaping competition?

Alkermes, Lundbeck, Indivior, Otsuka, and Alvogen dominate with blockbuster drugs like Vivitrol and Selincro; digital players such as Pear Therapeutics and DynamiCare Health redefine future technology-driven care pathways.

7. Where do future opportunities lie?

Personalized addiction genomics, depot-injectable generics, real-time biosensor monitoring, and value-based payment contracts present high-margin niches within the Alcohol Use Disorder Treatment market size expansion narrative.

8. How is technology impacting treatment paradigms?

AI-driven predictive relapse algorithms, smartphone-based cognitive behavioral therapy, and blockchain-secured prescription monitoring systems enhance adherence and outcomes, redefining the future outlook of AUD management.

9. What does the regulatory landscape look like?

FDA fast-track designation for depot formulations, DEA rescheduling of marijuana-derived therapeutics, and evolving state parity laws mandating coverage parity collectively shape Alcohol Use Disorder Treatment market dynamics.

10. Will generic competition erode market value?

While oral agents face steep LOE cliffs, patent-protected long-acting injectables and digital therapeutics create differentiated segments, sustaining overall Alcohol Use Disorder Treatment market size expansion beyond 2030.

Contact for Full Report

Loading report content...

What Is the Global Alcohol Use Disorder Treatment Market Worth in 2026?

Market Snapshot

Alcohol Use Disorder Treatment Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Alcohol Use Disorder Treatment Segmentation

Alcohol Use Disorder Treatment Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Alcohol Use Disorder Treatment market size?

2. What growth rate is forecast through 2030?

3. Which factors are the primary market drivers?

4. What challenges restrain faster expansion?

5. Which regions lead consumption and innovation?

6. Who are the top companies shaping competition?

7. Where do future opportunities lie?

8. How is technology impacting treatment paradigms?

9. What does the regulatory landscape look like?

10. Will generic competition erode market value?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Alcohol Use Disorder Treatment Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Alcohol Use Disorder Treatment Segmentation

Alcohol Use Disorder Treatment Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Alcohol Use Disorder Treatment market size?

2. What growth rate is forecast through 2030?

3. Which factors are the primary market drivers?

4. What challenges restrain faster expansion?

5. Which regions lead consumption and innovation?

6. Who are the top companies shaping competition?

7. Where do future opportunities lie?

8. How is technology impacting treatment paradigms?

9. What does the regulatory landscape look like?

10. Will generic competition erode market value?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation